f8k060713_actinium.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 7, 2013

ACTINIUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware
  
000-52446
  
000-52446
(State or other jurisdiction of
incorporation)
  
(Commission File Number)
  
(IRS Employer Identification No.)

501 Fifth Avenue, 3rd Floor
New York, NY
  
10017
(Address of principal executive offices)
  
(Zip Code)

Registrant’s telephone number, including area code: (212) 300-2131

Actinium Pharmaceuticals, Inc.
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
 
 
 
 
 
Item 8.01. Other Events.

Actinium Pharmaceuticals, Inc., a Delaware company, issued a press release on June 7, 2013 announcing the proceeds received from the exercise of its Series A Warrants. A copy of the press release is attached to this Form 8-K as Exhibit 99.1.
 
Item 9.01. Financial Statements and Exhibits.
 
(d) Exhibits.  
 
Exhibit 99.1
  
Press release of Actinium Pharmaceuticals, Inc. dated June 7, 2013.
 
 
2
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated: June 7, 2013
ACTINIUM PHARMACEUTICALS, INC.
  
       
 
By:
/s/ Sergio Traversa
  
   
Sergio Traversa
  
   
Interim President, Interim Chief Executive Officer, and Interim Chief Financial Officer
  
 
 
3